Platelets and protease-activated receptor-4 contribute to acetaminophen-induced liver injury in mice

Blood

Volumn 126, Issue 15, 2015, Pages 1835-1845

  Miyakawa, Kazuhisa ^a   Joshi, Nikita ^a,b   Sullivan, Bradley P ^a   Albee, Ryan ^b   Brandenberger, Christina ^a,d   Jaeschke, Hartmut ^c   McGill, Mitchell R ^c   Scott, Michael A ^a   Ganey, Patricia E ^a,b   Luyendyk, James P ^a   Roth, Robert A ^a,b  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

^c UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^d HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3 NITROTYROSINE; ALANINE AMINOTRANSFERASE; ANTIBODY; FIBRINOGEN RECEPTOR ANTAGONIST; HYALURONIC ACID; LEPIRUDIN; PARACETAMOL; PROTEINASE ACTIVATED RECEPTOR 4; THROMBIN; THROMBIN ANTITHROMBIN COMPLEX; ANALGESIC AGENT; ANTITHROMBIN III; ANTITHROMBIN III-PROTEASE COMPLEX; PEPTIDE HYDROLASE; PROTEASE-ACTIVATED RECEPTOR 4, MOUSE; PROTEINASE ACTIVATED RECEPTOR;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; DRUG METABOLISM; DRUG OVERDOSE; ENDOTHELIUM INJURY; HEMATOPOIETIC CELL; LIVER CELL DAMAGE; LIVER NECROSIS; LIVER TOXICITY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SIGNAL TRANSDUCTION; THROMBOCYTE; THROMBOCYTOPENIA; TOXIC HEPATITIS; WILD TYPE; ANIMAL; C57BL MOUSE; CELL CULTURE; CHEMICAL AND DRUG INDUCED LIVER INJURY; DRUG EFFECTS; ENZYME IMMUNOASSAY; HEMATOPOIETIC STEM CELL; KNOCKOUT MOUSE; LIVER CELL; METABOLISM; PATHOLOGY; PHYSIOLOGY; WESTERN BLOTTING;

ACETAMINOPHEN; ANALGESICS, NON-NARCOTIC; ANIMALS; ANTITHROMBIN III; BLOOD COAGULATION; BLOOD PLATELETS; BLOTTING, WESTERN; CELLS, CULTURED; CHEMICAL AND DRUG INDUCED LIVER INJURY; HEMATOPOIETIC STEM CELLS; HEPATOCYTES; IMMUNOENZYME TECHNIQUES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PEPTIDE HYDROLASES; RECEPTORS, PROTEINASE-ACTIVATED;

EID: 84943639024     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-09-598656     Document Type: Article

References (57)

1. Ostapowicz G, Fontana RJ, Schiødt FV, et al; U.S. Acute Liver Failure Study Group. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med. 2002;137(12):947-954.
2. Khashab M, Tector AJ, Kwo PY. Epidemiology of acute liver failure. Curr Gastroenterol Rep. 2007; 9(1):66-73.
3. Fontana RJ. Acute liver failure including acetaminophen overdose. Med Clin North Am. 2008;92(4):761-794, viii.
4. Karvellas CJ, Safinia N, Auzinger G, et al. Medical and psychiatric outcomes for patients transplanted for acetaminophen-induced acute liver failure: a case-control study. Liver Int. 2010; 30(6):826-833.
5. Mitchell JR, Jollow DJ, Potter WZ, Davis DC, Gillette JR, Brodie BB. Acetaminophen-induced hepatic necrosis. I. Role of drug metabolism. J Pharmacol Exp Ther. 1973;187(1):185-194.
6. Jollow DJ, Mitchell JR, Potter WZ, Davis DC, Gillette JR, Brodie BB. Acetaminophen-induced hepatic necrosis. II. Role of covalent binding in vivo. J Pharmacol Exp Ther. 1973;187(1): 195-202.
7. Potter WZ, Davis DC, Mitchell JR, Jollow DJ, Gillette JR, Brodie BB. Acetaminophen-induced hepatic necrosis. 3. Cytochrome P-450-mediated covalent binding in vitro. J Pharmacol Exp Ther. 1973;187(1):203-210.
8. Jaeschke H, Williams CD, Ramachandran A, Bajt ML. Acetaminophen hepatotoxicity and repair: the role of sterile inflammation and innate immunity. Liver Int. 2012;32(1):8-20.
9. Jaeschke H, McGill MR, Williams CD, Ramachandran A. Current issues with acetaminophen hepatotoxicity-a clinically relevant model to test the efficacy of natural products. Life Sci. 2011;88(17-18):737-745.
10. Hinson JA, Roberts DW, James LP. Mechanisms of acetaminophen-induced liver necrosis. Handbook Exp Pharmacol. 2010;(196):369-405.
11. James LP, Mayeux PR, Hinson JA. Acetaminophen-induced hepatotoxicity. Drug Metab Dispos. 2003;31(12):1499-1506.
12. Lee WM. Acute liver failure. N Engl J Med. 1993; 329(25):1862-1872.
13. Larson AM, Polson J, Fontana RJ, et al; Acute Liver Failure Study Group. Acetaminopheninduced acute liver failure: results of a United States multicenter, prospective study. Hepatology. 2005;42(6):1364-1372.
14. Ganey PE, Luyendyk JP, Newport SW, et al. Role of the coagulation system in acetaminopheninduced hepatotoxicity in mice. Hepatology. 2007; 46(4):1177-1186.
15. Sullivan BP, Kopec AK, Joshi N, et al. Hepatocyte tissue factor activates the coagulation cascade in mice. Blood. 2013;121(10):1868-1874.
16. Hugenholtz GC, Adelmeijer J, Meijers JC, Porte RJ, Stravitz RT, Lisman T. An unbalance between von Willebrand factor and ADAMTS13 in acute liver failure: implications for hemostasis and clinical outcome. Hepatology. 2013;58(2): 752-761.
17. Coughlin SR. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost. 2005;3(8):1800-1814.
18. Kahn ML, Nakanishi-Matsui M, Shapiro MJ, Ishihara H, Coughlin SR. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest. 1999;103(6): 879-887.
19. Kahn ML, Zheng YW, Huang W, et al. A dual thrombin receptor system for platelet activation. Nature. 1998;394(6694):690-694.
20. Sambrano GR, Weiss EJ, Zheng YW, Huang W, Coughlin SR. Role of thrombin signalling in platelets in haemostasis and thrombosis. Nature. 2001;413(6851):74-78.
21. Sullivan BP, Wang R, Tawfik O, Luyendyk JP. Protective and damaging effects of platelets in acute cholestatic liver injury revealed by depletion and inhibition strategies. Toxicol Sci. 2010;115(1): 286-294.
22. Kassel KM, Owens AP III, Rockwell CE, et al. Protease-activated receptor 1 and hematopoietic cell tissue factor are required for hepatic steatosis in mice fed a Western diet. Am J Pathol. 2011; 179(5):2278-2289.
23. Tschanz SA, Burri PH, Weibel ER. A simple tool for stereological assessment of digital images: the STEPanizer. J Microsc. 2011;243(1):47-59.
24. Joshi N, Kopec AK, O'Brien KM, et al. Coagulation-driven platelet activation reduces cholestatic liver injury and fibrosis in mice. J Thromb Haemost. 2015;13(1):57-71.
25. Kassel KM, Sullivan BP, Cui W, Copple BL, Luyendyk JP. Therapeutic administration of the direct thrombin inhibitor argatroban reduces hepatic inflammation in mice with established fatty liver disease. Am J Pathol. 2012;181(4): 1287-1295.
26. Lever R, Page CP. Non-anticoagulant effects of heparin: an overview. Handbook Exp Pharmacol. 2012;(207):281-305.
27. Greinacher A. Lepirudin: a bivalent direct thrombin inhibitor for anticoagulation therapy. Expert Rev Cardiovasc Ther. 2004;2(3):339-357.
28. Knight TR, Kurtz A, Bajt ML, Hinson JA, Jaeschke H. Vascular and hepatocellular peroxynitrite formation during acetaminophen toxicity: role of mitochondrial oxidant stress. Toxicological Sci. 2001;62(2):212-220.
29. Meli R, Raso GM, Cicala C, Esposito E, Fiorino F, Cirino G. Thrombin and PAR-1 activating peptide increase iNOS expression in cytokine-stimulated C6 glioma cells. J Neurochem. 2001;79(3): 556-563.
30. Touyz RM. Regulation of endothelial nitric oxide synthase by thrombin. Hypertension. 2007;49(3): 429-431.
31. Momota F, Hirano K, Hirano M, Nishimura J, Kanaide H. Involvement of Gi/o in the PAR-4- induced NO production in endothelial cells. Biochem Biophys Res Commun. 2006;342(2): 365-371.
32. Jaeschke H. Glutathione disulfide formation and oxidant stress during acetaminophen-induced hepatotoxicity in mice in vivo: the protective effect of allopurinol. J Pharmacol Exp Ther. 1990; 255(3):935-941.
33. Chiu H, Gardner CR, Dambach DM, et al. Role of p55 tumor necrosis factor receptor 1 in acetaminophen-induced antioxidant defense. Am J Physiol Gastrointest Liver Physiol. 2003;285(5): G959-G966.
34. Saito C, Zwingmann C, Jaeschke H. Novel mechanisms of protection against acetaminophen hepatotoxicity in mice by glutathione and Nacetylcysteine. Hepatology. 2010;51(1):246-254.
35. Jaeschke H, Liu J. Neutrophil depletion protects against murine acetaminophen hepatotoxicity: another perspective. Hepatology. 2007;45(6): 1588-1589, author reply 1589.
36. Hamilton JR, Cornelissen I, Coughlin SR. Impaired hemostasis and protection against thrombosis in protease-activated receptor 4- deficient mice is due to lack of thrombin signaling in platelets. J Thromb Haemost. 2004;2(8): 1429-1435.
37. Rezaie AR. Protease-activated receptor signalling by coagulation proteases in endothelial cells. Thromb Haemost. 2014;112(5):876-882.
38. Kataoka H, Hamilton JR, McKemy DD, et al. Protease-activated receptors 1 and 4 mediate thrombin signaling in endothelial cells. Blood. 2003;102(9):3224-3231.
39. O'Brien PJ, Prevost N, Molino M, et al. Thrombin responses in human endothelial cells. Contributions from receptors other than PAR1 include the transactivation of PAR2 by thrombincleaved PAR1. J Biol Chem. 2000;275(18): 13502-13509.
40. Williams AM, Langley PG, Osei-Hwediah J, Wendon JA, Hughes RD. Hyaluronic acid and endothelial damage due to paracetamol-induced hepatotoxicity. Liver Int. 2003;23(2):110-115.
41. Ito Y, Bethea NW, Abril ER, McCuskey RS. Early hepatic microvascular injury in response to acetaminophen toxicity. Microcirculation. 2003; 10(5):391-400.
42. DeLeve LD, Wang X, Kaplowitz N, Shulman HM, Bart JA, van der Hoek A. Sinusoidal endothelial cells as a target for acetaminophen toxicity. Direct action versus requirement for hepatocyte activation in different mouse strains. Biochem Pharmacol. 1997;53(9):1339-1345.
43. Hirano K, Nomoto N, Hirano M, Momota F, Hanada A, Kanaide H. Distinct Ca21 requirement for NO production between proteinase-activated receptor 1 and 4 (PAR1 and PAR4) in vascular endothelial cells. J Pharmacol Exp Ther. 2007; 322(2):668-677.
44. James LP, McCullough SS, Knight TR, Jaeschke H, Hinson JA. Acetaminophen toxicity in mice lacking NADPH oxidase activity: role of peroxynitrite formation and mitochondrial oxidant stress. Free Radic Res. 2003;37(12):1289-1297.
45. Hinson JA, Reid AB, McCullough SS, James LP. Acetaminophen-induced hepatotoxicity: role of metabolic activation, reactive oxygen/nitrogen species, and mitochondrial permeability transition. Drug Metab Rev. 2004;36(3-4):805-822.
46. Zarbock A, Polanowska-Grabowska RK, Ley K. Platelet-neutrophil-interactions: linking hemostasis and inflammation. Blood Rev. 2007;21(2):99-111.
47. Yadav SS, Howell DN, Steeber DA, Harland RC, Tedder TF, Clavien PA. P-Selectin mediates reperfusion injury through neutrophil and platelet sequestration in the warm ischemic mouse liver. Hepatology. 1999;29(5):1494-1502.
48. Laschke MW, Dold S, Menger MD, Jeppsson B, Thorlacius H. Platelet-dependent accumulation of leukocytes in sinusoids mediates hepatocellular damage in bile duct ligation-induced cholestasis. Br J Pharmacol. 2008;153(1):148-156.
49. Krenkel O, Mossanen JC, Tacke F. Immune mechanisms in acetaminophen-induced acute liver failure. Hepatobiliary Surg Nutr. 2014;3(6): 331-343.
50. Williams CD, Bajt ML, Sharpe MR, McGill MR, Farhood A, Jaeschke H. Neutrophil activation during acetaminophen hepatotoxicity and repair in mice and humans. Toxicol Appl Pharmacol. 2014; 275(2):122-133.
51. Jaeschke H. Role of inflammation in the mechanism of acetaminophen-induced hepatotoxicity. Expert Opin Drug Metab Toxicol. 2005;1(3):389-397.
52. Imaeda AB, Watanabe A, Sohail MA, et al. Acetaminophen-induced hepatotoxicity in mice is dependent on Tlr9 and the Nalp3 inflammasome. J Clin Invest. 2009;119(2):305-314.
53. Ben-Zvi Z, Weissman-Teitellman B, Katz S, Danon A. Acetaminophen hepatotoxicity: is there a role for prostaglandin synthesis? Arch Toxicol. 1990;64(4):299-304.
54. Tomishima Y, Ishitsuka Y, Matsunaga N, et al. Ozagrel hydrochloride, a selective thromboxane A2 synthase inhibitor, alleviates liver injury induced by acetaminophen overdose in mice. BMC Gastroenterol. 2013;13:21.
55. Guarner F, Boughton-Smith NK, Blackwell GJ, Moncada S. Reduction by prostacyclin of acetaminophen-induced liver toxicity in the mouse. Hepatology. 1988;8(2):248-253.
56. Reilly TP, Brady JN, Marchick MR, et al. A protective role for cyclooxygenase-2 in druginduced liver injury in mice. Chem Res Toxicol. 2001;14(12):1620-1628.
57. Chen J, Reheman A, Gushiken FC, et al. N-acetylcysteine reduces the size and activity of von Willebrand factor in human plasma and mice. J Clin Invest. 2011;121(2):593-603.